Positive Progress Across Johnson & Johnson's Multiple Pipeline Products; Target Price Raised to $275

Overview

This report summarizes key updates from Johnson & Johnson at the 47th Annual Global Healthcare Conference, covering latest developments in core product lines across immunology, oncology, and cardiovascular sectors. Goldman Sachs views the company's pipeline execution as strong, with multiple blockbuster drugs showing growth potential, leading to a maintained Buy rating and a raised target price of $275.

Core views

Immunology: Icotyde launch progressing well; prescribing physician count grew from 1,000 in Q1 to 4,500 currently, accelerating patient access (available within 24 hours for some); DTC campaign imminent. Positioned as first-line systemic therapy for early-stage disease, offering advantages such as complete skin clearance, placebo-like adverse events, and no mandatory TB testing. JNJ-4804 (a bispecific antibody targeting IL-23 and TNF) demonstrated significant efficacy in DUET trials among refractory IBD patients (approx. 1 million population), positioned as second-line or beyond treatment. Oncology: ERLEADA achieved double-digit growth; real-world data shows overall survival advantage over other ARPIs when used in combination. PROTEUS data (12 months pre- and post-operative treatment for high-risk localized prostate cancer) shows a 20% risk reduction, considered practice-changing data with potential brand halo effect. INLEXZO provider usage increased 50% after J-code implementation, with fill rates up 90%; currently indicated for approx. 3,000 patients with BCG-unresponsive NMIBC, with further expansion via SunRISe and MoonRISe trials targeting a potential market >$5 billion. Cardiovascular: Milvexian project proceeding smoothly; AF trial readout expected year-end. Management considers a 30-40% bleeding risk reduction clinically significant, potentially creating a >$5 billion asset. Despite competition from Eliquis generics, management emphasizes value-based pricing.

Analysis framework

Goldman Sachs employs a line-by-line assessment of product portfolios, analyzing clinical data, market positioning, target patient populations, and commercialization progress for each core drug. Valuation utilizes the P/E multiple method, applying a 20x P/E to forecasted EPS for 2026-2028 to derive a 12-month target price of $275. The analysis logic emphasizes how continuous innovation capability and commercialization execution support valuation.

Methodology notes

• Competition and Strategy FrameworkProduct life cycle

  Assess growth potential of drugs at different lifecycle stages (launch, growth, maturity)

  The report analyzes growth drivers and risks for each drug based on its lifecycle stage (e.g., Icotyde in launch phase, ERLEADA in growth phase) to help investors understand the timing of contribution to overall performance.

• Valuation MethodologyPE/PEG valuation

  Calculate target price using P/E multiples based on forecasted EPS

  Goldman Sachs applies a 20x P/E to forecasted EPS for 2026-2028 to derive the $275 target price, a common valuation method in the pharmaceutical industry reflecting market expectations for earnings growth.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Johnson & Johnson (JNJ.US)

  Direct beneficiary: Core product lines show positive progress; target price raised

  Strengths

  Diversified product portfolio, strong commercialization capabilities, multiple blockbuster drugs in growth phase

  Weaknesses

  Patent expiration pressure on certain products; uncertainty surrounding talc litigation

  Comparison

  More robust pipeline in immunology and oncology compared to peers

  Risks

  Slower-than-expected new product rollout; litigation settlements exceeding expectations; macroeconomic impacts

Key data

• Target Price$275Based on 20x P/E of 2026-2028 EPS
• Current Stock Price$237.00Closing price as of June 9, 2026
• Icotyde Prescribing Physicians~4,500Significant increase from ~1,000 in Q1
• INLEXZO Usage Increase50%Provider usage increased following J-code implementation
• ERLEADA Risk Reduction20%PROTEUS data shows reduced risk for high-risk patients
• Milvexian Potential Peak Sales>$5BManagement sees significant potential in Afib and secondary stroke markets

Impact & implications

The report suggests that positive momentum in J&J's core product lines will support medium-term growth; successful commercialization in immunology and oncology can offset some patent expiration risks. If Milvexian clinical data meets targets, it could emerge as a new growth engine. Overall, the company's execution capability for innovative medicine pipelines will sustain its valuation premium.

Risks

• New product rollout may be slower than anticipated, failing to replace revenue from declining products
• Uncertainty in talc litigation could lead to higher-than-expected payouts and compress valuation multiples
• Macroeconomic environment and tariff issues may present external challenges

What to watch

• Patient acquisition metrics following the launch of Icotyde's DTC campaign
• Results of the Milvexian AF trial readout year-end
• Progress of INLEXZO indication expansion trials (SunRISe/MoonRISe)
• Synergistic effects of ERLEADA within the prostate cancer pipeline